The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will evaluate the safety and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin’s lymphoma (B-NHL). ATG-031, discovered and developed in-house by Antengene, is…